<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>394</serviceExecutionTime><Drug id="57017"><DrugName>Kinrix</DrugName><DrugNamesKey><Name id="42861498">Infanrix-IPV</Name><Name id="42868475">Kinrix</Name></DrugNamesKey><DrugSynonyms><Name><Value>Infanrix-IPV</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Kinrix</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Infanrix-DTPa-IPV</Value></Name></DrugSynonyms><CompanyOriginator id="19962">SmithKline Beecham plc</CompanyOriginator><CompaniesPrimary><Company id="28355">GlaxoSmithKline plc</Company></CompaniesPrimary><CompaniesSecondary><Company id="19962">SmithKline Beecham plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="57017" type="Drug"><TargetEntity id="427526" type="siDrug">DTPa-IPV</TargetEntity></SourceEntity><SourceEntity id="19962" type="Company"><TargetEntity id="5000780276" type="organizationId">Smithkline Beecham Ltd</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="272" type="ciIndication"><TargetEntity id="A80" type="ICD10"></TargetEntity><TargetEntity id="10036012" type="MEDDRA"></TargetEntity><TargetEntity id="D011051" type="MeSH"></TargetEntity><TargetEntity id="2912" type="ORPHANET"></TargetEntity><TargetEntity id="-250236249" type="omicsDisease"></TargetEntity><TargetEntity id="3005" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="47" type="ciIndication"><TargetEntity id="A37" type="ICD10"></TargetEntity><TargetEntity id="033" type="ICD9"></TargetEntity><TargetEntity id="10034738" type="MEDDRA"></TargetEntity><TargetEntity id="D014917" type="MeSH"></TargetEntity><TargetEntity id="1489" type="ORPHANET"></TargetEntity><TargetEntity id="-320620987" type="omicsDisease"></TargetEntity><TargetEntity id="2337" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="72" type="ciIndication"><TargetEntity id="10043376" type="MEDDRA"></TargetEntity><TargetEntity id="D013742" type="MeSH"></TargetEntity><TargetEntity id="3299" type="ORPHANET"></TargetEntity><TargetEntity id="-687302618" type="omicsDisease"></TargetEntity><TargetEntity id="816" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="81" type="ciIndication"><TargetEntity id="A36" type="ICD10"></TargetEntity><TargetEntity id="10013023" type="MEDDRA"></TargetEntity><TargetEntity id="D004165" type="MeSH"></TargetEntity><TargetEntity id="1679" type="ORPHANET"></TargetEntity><TargetEntity id="-360770994" type="omicsDisease"></TargetEntity><TargetEntity id="3234" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bordetella pertussis infection - EU - Jun-2004</FirstLaunched><FirstLaunched>Clostridium tetani infection - EU - Jun-2004</FirstLaunched><FirstLaunched>Corynebacterium diphtheriae infection - EU - Jun-2004</FirstLaunched><FirstLaunched>Poliovirus infection - EU - Jun-2004</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="272">Poliovirus infection</Indication><Indication id="47">Bordetella pertussis infection</Indication><Indication id="72">Clostridium tetani infection</Indication><Indication id="81">Corynebacterium diphtheriae infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="12378">Prophylactic vaccine</Action><Action id="12372">Protein subunit vaccine</Action><Action id="12375">Toxoid vaccine</Action><Action id="12367">Inactivated viral vaccine</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="175">Drug combination</Technology><Technology id="651">Intramuscular formulation</Technology></Technologies><LastModificationDate>2019-02-04T14:52:05.000Z</LastModificationDate><ChangeDateLast>2019-02-05T00:00:00.000Z</ChangeDateLast><AddedDate>2007-03-19T16:12:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; (GSK; formerly &lt;ulink linkID="19962" linkType="Company"&gt;SmithKline Beecham&lt;/ulink&gt;) has developed  and launched Kinrix (Infanrix-IPV), a tetravalent booster diphtheria, tetanus, pertussis (acellular) (DTPa) and poliomyelitis (inactivated; IPV) conjugate vaccine [&lt;ulink linkID="1793178" linkType="Reference"&gt;1793178&lt;/ulink&gt;]. The vaccine is indicated in the US for active immunization against diphtheria, tetanus, pertussis and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTPa) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with &lt;ulink linkID="6229" linkType="Drug"&gt;Infanrix&lt;/ulink&gt; and/or &lt;ulink linkID="17823" linkType="Drug"&gt;Pediarix&lt;/ulink&gt; for the first three doses and Infanrix for the fourth dose [&lt;ulink linkID="1793178" linkType="Reference"&gt;1793178&lt;/ulink&gt;]. In the EU, the vaccine vaccine is indicated for booster vaccination against diphtheria, tetanus, pertussis, and poliomyelitis diseases in individuals from 16 months to 13 years of age inclusive who have previously received primary immunisation series against these diseases [&lt;ulink linkID="775907" linkType="Reference"&gt;775907&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2000, the vaccine was approved in Belgium [&lt;ulink linkID="1448579" linkType="Reference"&gt;1448579&lt;/ulink&gt;]. In October 2001, the vaccine was registered in France [&lt;ulink linkID="1351868" linkType="Reference"&gt;1351868&lt;/ulink&gt;]. In June 2004, the vaccine was approved in Europe and presumed to have been launched [&lt;ulink linkID="775907" linkType="Reference"&gt;775907&lt;/ulink&gt;].   By the end of 3Q08, the vaccine had been launched in the US [&lt;ulink linkID="954914" linkType="Reference"&gt;954914&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;The vaccine was  submitted to the FDA as Kinrix, a pediatric booster vaccine for children of 4 to 6 years, in June 2007 [&lt;ulink linkID="815612" linkType="Reference"&gt;815612&lt;/ulink&gt;], [&lt;ulink linkID="804574" linkType="Reference"&gt;804574&lt;/ulink&gt;]. In June 2008, the FDA approved Kinrix for children who had previously been vaccinated with Pediarix and/or Infanrix [&lt;ulink linkID="919802" linkType="Reference"&gt;919802&lt;/ulink&gt;]; by the end of 3Q08, the vaccine had been launched [&lt;ulink linkID="954914" linkType="Reference"&gt;954914&lt;/ulink&gt;]. In July 2012, the FDA approved GSK's request to supplement the BLA to include updated information regarding instruction on  vaccine administration in the package insert [&lt;ulink linkID="1310265" linkType="Reference"&gt;1310265&lt;/ulink&gt;]. In November 2013, the FDA approved the sBLA of the vaccine to change  the product labelling in accordance to the guidance issued to inform the users that the product container was not made with natural rubber latex [&lt;ulink linkID="1506057" linkType="Reference"&gt;1506057&lt;/ulink&gt;]. In July 2014, the FDA approved GSK's request to supplement the BLA to include safety and immunogenicity data to support co-administration of Kinrix with &lt;ulink linkID="4645" linkType="Drug"&gt;Varivax&lt;/ulink&gt; in the revised package insert and to update the pharmacovigilance plan [&lt;ulink linkID="1580199" linkType="Reference"&gt;1580199&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2000, the vaccine was approved in Belgium [&lt;ulink linkID="1448579" linkType="Reference"&gt;1448579&lt;/ulink&gt;]. In October 2001, the vaccine was registered in France [&lt;ulink linkID="1351868" linkType="Reference"&gt;1351868&lt;/ulink&gt;]. In June 2004, the vaccine was approved in Europe and presumed to have been launched  [&lt;ulink linkID="775907" linkType="Reference"&gt;775907&lt;/ulink&gt;], [&lt;ulink linkID="1716965" linkType="Reference"&gt;1716965&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In June 2010, Korean approval was obtained  [&lt;ulink linkID="1134593" linkType="Reference"&gt;1134593&lt;/ulink&gt;]. Launch took place in May 2011 [&lt;ulink linkID="1205214" linkType="Reference"&gt;1205214&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2009, a randomized, open-label, parallel assigned, phase III trial (&lt;ulink linkID="50217" linkType="Protocol"&gt;NCT00871117&lt;/ulink&gt;, 111852) to study the immunogenicity and safety of Kinrix co-administered with Varivax, was initiated in healthy volunteers (n = 478), in the US. The study was completed in January 2010 [&lt;ulink linkID="1580361" linkType="Reference"&gt;1580361&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By June 2008, the vaccine had been shown in clinical trials, including a pivotal, phase III, US, randomized, controlled, 3156-subject trial, to provide similar protection and safety to diphtheria, tetanus toxoids and acellular pertussis (DTaP) and inactivated poliovirus (IPV) vaccines  which are administered  separately [&lt;ulink linkID="919802" linkType="Reference"&gt;919802&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase III trials were underway in the US by March 2007 [&lt;ulink linkID="772352" linkType="Reference"&gt;772352&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2002, a comparative, randomized, open-label,  phase II trial (&lt;ulink linkID="14412" linkType="Protocol"&gt;NCT00263692&lt;/ulink&gt;; 213503/047) was initiated in healthy infants of 4 to 6 years (expected n = 400) in the US. The subjects were to receive Infanrix-IPV coadministered with an MMR vaccine and compared to separate injections with Infanrix, IPV and MMR. The primary endpoint was immunogenicity and secondary endpoints included immunogenicity and safety. The study was completed by December 2005 [&lt;ulink linkID="775911" linkType="Reference"&gt;775911&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-04T00:00:00.000Z</StatusDate><Source id="775907" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-04T00:00:00.000Z</StatusDate><Source id="775907" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-04T00:00:00.000Z</StatusDate><Source id="775907" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-09-30T00:00:00.000Z</StatusDate><Source id="954914" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-31T00:00:00.000Z</StatusDate><Source id="1205214" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-31T00:00:00.000Z</StatusDate><Source id="1205214" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-04T00:00:00.000Z</StatusDate><Source id="775907" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-09-30T00:00:00.000Z</StatusDate><Source id="954914" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-09-30T00:00:00.000Z</StatusDate><Source id="954914" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-31T00:00:00.000Z</StatusDate><Source id="1205214" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-09-30T00:00:00.000Z</StatusDate><Source id="954914" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-31T00:00:00.000Z</StatusDate><Source id="1205214" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-08-07T00:00:00.000Z</StatusDate><Source id="1351868" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-08-07T00:00:00.000Z</StatusDate><Source id="1351868" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-08-07T00:00:00.000Z</StatusDate><Source id="1351868" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-08-07T00:00:00.000Z</StatusDate><Source id="1351868" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-04T00:00:00.000Z</StatusDate><Source id="775907" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-04T00:00:00.000Z</StatusDate><Source id="775907" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-04T00:00:00.000Z</StatusDate><Source id="775907" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-04T00:00:00.000Z</StatusDate><Source id="775907" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-13T00:00:00.000Z</StatusDate><Source id="1448579" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-13T00:00:00.000Z</StatusDate><Source id="1448579" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-13T00:00:00.000Z</StatusDate><Source id="1448579" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-13T00:00:00.000Z</StatusDate><Source id="1448579" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-11-30T00:00:00.000Z</StatusDate><Source id="775911" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-11-30T00:00:00.000Z</StatusDate><Source id="775911" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-11-30T00:00:00.000Z</StatusDate><Source id="775911" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-11-30T00:00:00.000Z</StatusDate><Source id="775911" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-02T00:00:00.000Z</StatusDate><Source id="772352" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-02T00:00:00.000Z</StatusDate><Source id="772352" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-02T00:00:00.000Z</StatusDate><Source id="772352" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-02T00:00:00.000Z</StatusDate><Source id="772352" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-30T00:00:00.000Z</StatusDate><Source id="815612" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-30T00:00:00.000Z</StatusDate><Source id="815612" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-30T00:00:00.000Z</StatusDate><Source id="815612" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-30T00:00:00.000Z</StatusDate><Source id="815612" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-24T00:00:00.000Z</StatusDate><Source id="919802" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-24T00:00:00.000Z</StatusDate><Source id="919802" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-24T00:00:00.000Z</StatusDate><Source id="882577" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-24T00:00:00.000Z</StatusDate><Source id="919802" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-06-30T00:00:00.000Z</StatusDate><Source id="1134593" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-06-30T00:00:00.000Z</StatusDate><Source id="1134593" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="272">Poliovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-06-30T00:00:00.000Z</StatusDate><Source id="1134593" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-06-30T00:00:00.000Z</StatusDate><Source id="1134593" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1570235" number="WO-09013313" title="Acellular vaccine."></PatentFamily><PatentFamily id="16422" number="EP-00162639" title="Antigenic preparations and isolation of such preparations."></PatentFamily><PatentFamily id="386010" number="WO-09115505" title="Purification Of A Pertussis Outer Membrane Protein"></PatentFamily><PatentFamily id="533955" number="EP-00377114" title="Method for preparing pertussis toxin toxoid."></PatentFamily><PatentFamily id="755495" number="WO-09112020" title="Novel vaccine and method therefor."></PatentFamily><PatentFamily id="922778" number="WO-2007131946" title="Detection method and kit"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kaketsuken" id="15374"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lederle Arzneimittel GmbH &amp; Co" id="DOL1000830"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>